 |
 |
|
| ||||||
About Adamas |
|
|
  Adamas Pharmaceuticals OverviewAdamas Pharmaceuticals is an emerging pharmaceutical company focused on developing small molecule Advantaged Therapeutics. Adamas Pharmaceuticals is headquartered in Emeryville, California, with operations in Bangalore, India. Adamas Pharmaceuticals was founded in 2004 to address diseases best treated by combination therapy by developing small molecule Advantaged Therapeutics to improve upon the standard of care. Advantaged Therapeutics are unique combination products — precisely calibrated fixed-dose formulations — that are designed to overcome the known limitations of monotherapy by improving tolerability, efficacy and to simplify daily drug regimens. Adamas uses known chemical entities and proven drug delivery techniques to create Advantaged Therapeutics for large, addressable markets. Recognition that combination therapies can address significant unmet needs is fueling growth of the almost $30 billion segment for combination therapeutics. Estimates suggest that the market will nearly double in the next decade, reaching $80 billion in 2019. Adamas is well-positioned to contribute to this growing market. Led by a management team with extensive pharmaceutical industry experience and more than 50 NDAs to its credit, Adamas' business strategy focuses on advancing market driven programs that emerge from the company's core competencies in discovery, formulation and clinical development. With this platform in place, Adamas has programs underway for large market opportunities where combination therapy offers significant advantages over monotherapy, including dementia and Parkinson's disease, and acute infectious diseases where resistance plays a major role, such as influenza. Three programs are in clinical development:
|
| ||
| ||
| ||
| ||
| ||
© 2010 Adamas Pharmaceuticals, Inc. | ||
| ||